As FDA kicked off the drug user fee reauthorization process, Commissioner Marty Makary said he’d like to see lower fees paid ...

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

The report provides a detailed analysis of the current acute pain marketed drugs and late-stage pipeline drugs. BROOKLYN, NY, UNITED STATES, July 15, 2025 /EINPresswire.com/ -- The acute pain market ...

Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) therapy has been recommended by the National Institute for ...

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, ...

Vertex struck a milestone deal with NHS England to make its cutting-edge cystic fibrosis drug ALYFTREK available to eligible ...

Ultragenyx's UX111 gene therapy faces FDA delay due to facility issues; analysts adjust price targets amid uncertain ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

While the CRL derails a near-term clearance, one analyst described the rejection as more of “a speed bump to approval, rather ...

The manufacturing-related rejection for UX111 is more than a setback for Ultragenyx, as it also delays a key test of the new ...

Advancements in gene editing, strategic partnerships, and supportive regulations fuel global CRISPR adoption across healthcare and agriculture. DELAWARE, DE, UNITED STATES, July 14, 2025 /EINPresswire ...

In his first 100 days as commissioner of the Food and Drug Administration, Marty Makary has made a handful of splashy ...